Back to Newsroom

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

LEXINGTON, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced the expansion of its pipeline with the addition of two programs, the first of which is an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), and the second is focused on inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4).

Click here to read more